Indications
Treatment of moderate to severe dry eye disease (keratoconjunctivitis sicca) in adult patients, which has not improved despite treatment with tear substitutes.
Composition
- Active substance
- ciclosporin
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vevizye
- Active substance
- ciclosporin
- ATC code
- S01XA18
- Group
- Sensory organs
- Therapeutic area
- Keratoconjunctivitis Sicca
- Marketing authorisation holder
- Laboratoires Théa
- Status
- Authorised
- EU authorisation
- 19 Sept 2024